Donate

Bispecific Antibodies for Lymphoma

Share

About Course

The series is designed to harness you with the most up-to-date information on bispecific antibody treatment, administration and management in patients with Lymphoma. It comprises of three modules presented by our guest speakers and experts in their field.

Course Content

Module 1: Foundations of Bispecific Antibodies for Lymphoma Care
Module one covers: Overview of lymphoma and evolving treatment landscape, Mechanism of action of bispecific antibodies, Indications and patient eligibility, Differences from other therapies (e.g. CAR-T), Introduction to treatment pathways

  • Module 1 Video
    53:22
  • Module 1 Quiz

Module 2: Patient Preparation & Safe Administration
Module two covers: Baseline patient assessment and risk stratification, Pre-medications and pre-treatment requirements, Patient education, Drug handling, preparation, and administration, Step-up dosing protocols, Inpatient vs outpatient, considerations and discharge planning, Shared care models

Module 3: Adverse Event Recognition & Management
Module 3 Covers: Cytokine Release Syndrome (CRS): recognition, grading, management, ICANS: early detection and escalation, Infection risks and other toxicities, Monitoring requirements post-administration, Emergency response and escalation pathways

Earn a certificate of attendance

The certificate will be emailed to you shortly after you have submitted the assessment.

selected template
Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.